What are the benefits of dasatinib tablets?

Chimeric origin from the Philadelphia chromosomeThe BCR-ABL gene encodes a fusion protein BCR-ABL with unregulated tyrosine kinase activity, which is a key pathogenesis step in chronic myelogenous leukemia (CML). Imatinib (imatinib) is a BCR-ABL tyrosine kinase inhibitor that can significantly improve the prognosis of patients with chronic myelogenous leukemia. Although most patients with chronic myelogenous leukemia respond to imatinib, a subset of patients do not respond or progress with accelerated or blast phase chronic myelogenous leukemia.

Understanding the mechanisms of resistance to imatinib has led to the development of newBCR-ABL inhibitors; among these drugs, dasatinib is the most promising, being approximately 300 times more potent than imatinib; it also inhibits SRC family kinases. Following the introduction of dasatinib in clinical trials, preliminary data in patients with chronic myelogenous leukemia indicate that the drug is safe and well tolerated; furthermore, the majority of patients with imatinib-resistant disease achieved objective responses, although the durability of responses remains to be determined. Recently, dasatinib emerged as a potent inhibitor of imatinib-resistant protein tyrosine kinase (KIT) activation loop mutants and was able to induce apoptosis in mast cells and leukemia cell lines expressing these mutations. Preclinical data on its activity in several human solid tumor cell lines broaden new opportunities for its applications beyond chronic myelogenous leukemia.

In general, dasatinib tablets have become a new drug in the treatment field of CML due to its strong efficacy, good safety and wide applicability. It not only overcomes the problem of imatinib resistance, but also provides new hope for patients who do not respond to traditional treatments.